# Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

> **NCT07722962** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Kringle Pharma, Inc.** · enrollment: 10 (estimated)

## Conditions studied

- Acute Spinal Cord Injury (SCI)

## Interventions

- **DRUG:** KP-100IT

## Key facts

- **NCT ID:** NCT07722962
- **Lead sponsor:** Kringle Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07722962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07722962, "Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07722962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*